Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

This publication has 25 references indexed in Scilit:

• Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
  The Lancet Oncology, 2009
• Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
  The Lancet, 2009
• Risk stratification of patients diagnosed with gastrointestinal stromal tumor
  Human Pathology, 2008
• Gastrointestinal stromal tumours (GIST) – 17 years experience from Mid Trent Region (United Kingdom)
  European Journal of Surgical Oncology, 2008
• Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
  Journal of Clinical Oncology, 2008
• Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study
  BMC Cancer, 2007
• An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors
  International Journal of Clinical Oncology, 2007
• Gastrointestinal stromal tumour
  The Lancet, 2007
• Mutations in gastrointestinal stromal tumors – a population‐based study from Northern Norway
  APMIS, 2007
• Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era
  Cancer, 2005